{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T01:35:17Z","timestamp":1792805717659,"version":"4.5.0"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,10,15]],"date-time":"2020-10-15T00:00:00Z","timestamp":1602720000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thebreastonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Breast"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.breast.2020.10.005","type":"journal-article","created":{"date-parts":[[2020,10,17]],"date-time":"2020-10-17T11:34:11Z","timestamp":1602934451000},"page":"171-178","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"special_numbering":"C","title":["Eligibility of real-world patients with metastatic breast cancer for clinical trials"],"prefix":"10.1016","volume":"54","author":[{"given":"Atul","family":"Batra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiying","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winson Y.","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.breast.2020.10.005_bib1","doi-asserted-by":"crossref","first-page":"219","DOI":"10.5455\/aim.2008.16.219-225","article-title":"Evidence based medicine \u2013 New approaches and challenges","volume":"16","author":"Masic","year":"2008","journal-title":"Acta Inf Med"},{"key":"10.1016\/j.breast.2020.10.005_bib2","doi-asserted-by":"crossref","first-page":"s41","DOI":"10.7861\/clinmedicine.18-2-s41","article-title":"Recent advances in the management of lung cancer","volume":"18","author":"Jones","year":"2018","journal-title":"Clin Med"},{"key":"10.1016\/j.breast.2020.10.005_bib3","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1182\/blood-2007-10-116129","article-title":"Improved survival in multiple myeloma and the impact of novel therapies","volume":"111","author":"Kumar","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.breast.2020.10.005_bib4","doi-asserted-by":"crossref","first-page":"3745","DOI":"10.1200\/JCO.2017.73.4186","article-title":"Re-evaluating eligibility criteria for oncology clinical trials: analysis of investigational New drug applications in 2015","volume":"35","author":"Jin","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.breast.2020.10.005_bib5","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1038\/leu.2016.374","article-title":"The relationship between eligibility criteria and adverse events in randomized controlled trials of hematologic malignancies","volume":"31","author":"Statler","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.breast.2020.10.005_bib6","doi-asserted-by":"crossref","first-page":"e160","DOI":"10.1016\/j.clon.2019.05.003","article-title":"Generalisability of common oncology clinical trial eligibility criteria in the real world","volume":"31","author":"Karim","year":"2019","journal-title":"Clin Oncol"},{"key":"10.1016\/j.breast.2020.10.005_bib7","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1200\/EDBK_156686","article-title":"Role of clinical trial participation in cancer research: barriers, evidence, and strategies","volume":"35","author":"Unger","year":"2016","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.breast.2020.10.005_bib8","doi-asserted-by":"crossref","DOI":"10.3747\/co.25.3978","article-title":"Are clinical trial eligibility criteria an accurate reflection of a real-world population of advanced non-small-cell lung cancer patients?","volume":"25","author":"Al-Baimani","year":"2018","journal-title":"Curr Oncol"},{"key":"10.1016\/j.breast.2020.10.005_bib9","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1093\/annonc\/mdr443","article-title":"The eligibility of advanced non-small-cell lung cancer patients for targeted therapy clinical trials","volume":"23","author":"Clarey","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2020.10.005_bib10","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1200\/JOP.2013.001194","article-title":"Use of the national cancer Institute community cancer centers program screening and accrual log to address cancer clinical trial accrual","volume":"10","author":"St Germain","year":"2014","journal-title":"JOP"},{"key":"10.1016\/j.breast.2020.10.005_bib11","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1038\/bjc.2012.46","article-title":"Comorbidity in elderly cancer patients in relation to overall and cancer-specific mortality","volume":"106","author":"J\u00f8rgensen","year":"2012","journal-title":"Br J Canc"},{"key":"10.1016\/j.breast.2020.10.005_bib12","doi-asserted-by":"crossref","DOI":"10.3747\/co.26.5625","article-title":"Role of real-world evidence in informing cancer care: lessons from colorectal cancer","volume":"26","author":"Batra","year":"2019","journal-title":"Curr Oncol"},{"key":"10.1016\/j.breast.2020.10.005_bib13","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1056\/NEJMoa1413513","article-title":"Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer","volume":"372","author":"Swain","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.breast.2020.10.005_bib14","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1056\/NEJMoa1810527","article-title":"Overall survival with palbociclib and fulvestrant in advanced breast cancer","volume":"379","author":"Turner","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.breast.2020.10.005_bib15","doi-asserted-by":"crossref","DOI":"10.1093\/jncics\/pky062","article-title":"Change in survival in metastatic breast cancer with treatment advances: meta-analysis and systematic review","volume":"2","author":"Caswell-Jin","year":"2018","journal-title":"JNCI Cancer Spectr"},{"key":"10.1016\/j.breast.2020.10.005_bib16","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"Ca - Cancer J Clin"},{"key":"10.1016\/j.breast.2020.10.005_bib17","doi-asserted-by":"crossref","first-page":"452","DOI":"10.6004\/jnccn.2020.0016","article-title":"Breast cancer, version 3.2020, NCCN clinical practice guidelines in oncology","volume":"18","author":"Gradishar","year":"2020","journal-title":"J\u00a0Natl Compr Canc Netw"},{"key":"10.1016\/j.breast.2020.10.005_bib18","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1093\/annonc\/mdy192","article-title":"4th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 4)\u2020","volume":"29","author":"Cardoso","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2020.10.005_bib19","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0040296","article-title":"The strengthening the reporting of observational studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"4","author":"von Elm","year":"2007","journal-title":"PLoS Med"},{"key":"10.1016\/j.breast.2020.10.005_bib20","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","article-title":"Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data","volume":"43","author":"Quan","year":"2005","journal-title":"Medical Care"},{"key":"10.1016\/j.breast.2020.10.005_bib21","article-title":"Multicollinearity in regression analyses conducted in epidemiologic studies","volume":"6","author":"Vatcheva","year":"2016","journal-title":"Epidemiology"},{"key":"10.1016\/j.breast.2020.10.005_bib22","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1097\/00000421-199902000-00011","article-title":"Accrual to breast cancer clinical trials at a university-affiliated hospital in metropolitan Detroit","volume":"22","author":"Simon","year":"1999","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.breast.2020.10.005_bib24","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0140-6736(12)60240-2","article-title":"Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study","volume":"380","author":"Barnett","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.breast.2020.10.005_bib25","first-page":"3737","article-title":"Broadening eligibility criteria to make clinical trials more representative: American society of clinical oncology and Friends of cancer research joint research statement","volume":"35","author":"Kim","year":"2017","journal-title":"J\u00a0Clin Orthod"},{"key":"10.1016\/j.breast.2020.10.005_bib26","doi-asserted-by":"crossref","DOI":"10.1111\/j.1532-5415.2009.02503.x","article-title":"Geriatric assessment in oncology practice","volume":"57","author":"Hurria","year":"2009","journal-title":"J\u00a0Am Geriatr Soc"},{"key":"10.1016\/j.breast.2020.10.005_bib27","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1200\/JCO.2002.20.2.494","article-title":"Comprehensive geriatric assessment adds information to Eastern Cooperative Oncology Group performance status in elderly cancer patients: an Italian Group for Geriatric Oncology Study","volume":"20","author":"Repetto","year":"2002","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.breast.2020.10.005_bib28","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1093\/annonc\/mds619","article-title":"Relevance of a systematic geriatric screening and assessment in older patients with cancer: results of a prospective multicentric study","volume":"24","author":"Kenis","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2020.10.005_bib29","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1634\/theoncologist.5-3-224","article-title":"Management of cancer in the older person: a practical approach","volume":"5","author":"Balducci","year":"2000","journal-title":"Oncol"},{"key":"10.1016\/j.breast.2020.10.005_bib30","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.critrevonc.2010.08.004","article-title":"Influence of geriatric consultation with comprehensive geriatric assessment on final therapeutic decision in elderly cancer patients","volume":"79","author":"Cha\u00efbi","year":"2011","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.breast.2020.10.005_bib31","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1093\/annonc\/mdq220","article-title":"Survival differences among women with de novo stage IV and relapsed breast cancer","volume":"21","author":"Dawood","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2020.10.005_bib32","first-page":"353","volume":"vol. 32","author":"Yamamura","year":"2018"}],"container-title":["The Breast"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S096097762030196X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S096097762030196X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T08:42:54Z","timestamp":1760776974000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S096097762030196X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":31,"alternative-id":["S096097762030196X"],"URL":"https:\/\/doi.org\/10.1016\/j.breast.2020.10.005","relation":{},"ISSN":["0960-9776"],"issn-type":[{"value":"0960-9776","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Eligibility of real-world patients with metastatic breast cancer for clinical trials","name":"articletitle","label":"Article Title"},{"value":"The Breast","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.breast.2020.10.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}